Outcomes
pneumonia, headache, anxiety
PNEUMONIA, ADVERSE EVENTS, INTRACRANIAL HEMORRHAGE, ADVERSE EVENT, EVENTS
In the original design, the primary endpoint was the proportion of excellent functional outcome, defined as an mRS score of 0–1 at 90 days (Supplementary Note Prespecified safety outcomes included any adverse events and serious adverse events during HDP, such as patient fear, headache, anxiety, intracranial hemorrhage, cardiopulmonary events, and pneumonia, which were not present at the beginning of the study. Adverse events with HDP were adjudicated by the chairman of the data safety monitoring board (YLW).